CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients

CG Oncology announced positive Phase 2 results from CORE-008 Cohort CX evaluating intravesical cretostimogene combined with gemcitabine in high-risk BCG-exposed and BCG-unresponsive bladder cancer patients. The trial demonstrated high complete response rates (85.7-92.3%), high-grade event-free survival of 96.0% at 3 months and 89.5% at 6 months, with a favorable safety profile and no Grade 3+ treatment-related adverse events.

05/15/2026, 8:00 AM • GlobeNewswire

Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026

The oncology landscape is experiencing rapid regulatory advancement as precision medicine and genomics expand significantly. Multiple biotech companies are advancing cancer therapies toward accelerated FDA approvals in 2026, with the precision medicine market projected to grow from $138.67 billion in 2026 to $537.17 billion by 2035. Key developments include Oncolytics' pelareorep showing strong response rates in anal cancer, CG Oncology's Phase 3 trial ahead of schedule, Zentalis advancing azenosertib in ovarian cancer, ArriVent initiating a pivotal Phase 3 study for firmonertinib, and PDS Biotechnology gaining FDA alignment on trial endpoints.

01/12/2026, 10:35 AM • Benzinga

CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference

CG Oncology announced that its Chairman & CEO Arthur Kuan and President & COO Ambaw Bellete will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. The company is a late-stage clinical biopharmaceutical firm developing bladder-sparing therapeutics for bladder cancer patients, with recent data showing promising efficacy rates for its lead candidate cretostimogene grenadenorepvec in non-muscle invasive bladder cancer.

01/06/2026, 8:00 AM • GlobeNewswire

CG Oncology Announces New Board Member and Board Transition

CG Oncology appointed Christina Rossi, an accomplished life sciences executive with 25 years of pharmaceutical experience, to its Board of Directors. Simultaneously, Simone Song resigned from the board, marking a leadership transition as the company prepares for potential FDA approval of its bladder cancer therapeutic.

11/26/2025, 7:00 AM • GlobeNewswire

CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates

CG Oncology initiated a rolling Biologics License Application for cretostimogene, a potential bladder cancer treatment, demonstrating promising 24-month complete response rates and completing enrollment in a Phase 3 clinical trial for non-muscle invasive bladder cancer.

11/14/2025, 8:00 AM • GlobeNewswire

Why Cg Oncology Stock Rocketed 7% Higher Today

Guggenheim initiated coverage on CG Oncology with a buy rating and $90 price target, highlighting the company's promising investigational drug for non-muscle invasive bladder cancer treatment.

10/08/2025, 6:14 PM • The Motley Fool

CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months

CG Oncology reported promising 24-month results for cretostimogene, a potential bladder cancer treatment, showing a 41.8% complete response rate in high-risk non-muscle invasive bladder cancer patients unresponsive to previous treatments.

09/05/2025, 7:00 AM • GlobeNewswire

CG Oncology Completes Enrollment in PIVOT-006

CG Oncology announced completion of enrollment in its Phase 3 PIVOT-006 study, comparing an innovative intravesical therapy for intermediate-risk non-muscle invasive bladder cancer, with over 360 patients enrolled across 90+ sites.

09/03/2025, 8:00 AM • GlobeNewswire

CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences

CG Oncology announced that its leadership will participate in two upcoming investor conferences in September 2025, presenting at the Cantor Global Healthcare Conference and Morgan Stanley 23rd Annual Global Healthcare Conference.

08/29/2025, 8:00 AM • GlobeNewswire

Cg Oncology (CGON) Q2 Loss Widens 93%

Cg Oncology reported a wider net loss in Q2 2025, with no revenue and increased R&D expenses. The company continues developing a gene therapy for bladder cancer and plans to submit a Biologics License Application in Q4 2025.

08/08/2025, 8:25 AM • The Motley Fool